Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY -5.15%20 EV-to-OCF is 201.15 as of Sep. 03, 2026. GuruFocus rates BTCY with a GF Score™ of 20/100 and a GF Value™ of $0.37 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Biotricity ranks worse than 98.24% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Biotricity's Enterprise Value is $32.59 Mil.
Biotricity's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $0.16 Mil. Therefore, Biotricity's EV-to-OCF for today is 201.15.
The historical rank and industry rank for Biotricity's EV-to-OCF or its related term are showing as below:
BTCY'
s EV-to-OCF Range Over the Past 10 Years
Min: -100.74 Med: -5.81 Max: 208.88
Current: 201.15
During the past 13 years, the highest EV-to-OCF of Biotricity was 208.88. The lowest was -100.74. And the median was -5.81.
BTCY's EV-to-OCF is ranked worse than 98.24% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.815
vs BTCY: 201.15
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotricity's share price for today is $0.09845.
Biotricity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.133.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biotricity EV-to-OCF Related Terms
Biotricity EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Biotricity's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biotricity's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Biotricity's EV-to-OCF falls into.
Biotricity's current Enterprise Value is $32.59 Mil.
Biotricity's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a EV-to-OCF of 201.15 as of Sep. 03, 2026. According to the industry distribution chart, Biotricity ranks #835 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is Biotricity's EV-to-OCF too high?
Biotricity's current EV-to-OCF is 201.15. The Medical Devices & Instruments industry median EV-to-OCF is 7.82. Biotricity's value of 201.15 is 2473.9% above this industry median. Based on the distribution chart, Biotricity ranks #835 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biotricity has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's EV-to-OCF compare to IVF and CSDX?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #835 out of 850 companies for EV-to-OCF. This places Biotricity in the lower half of its industry. The industry median EV-to-OCF is 7.82. Biotricity's value of 201.15 is 2473.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.82, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotricity's current EV-to-OCF of 201.15 is 2473.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotricity's current EV-to-OCF is 201.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.37, compared to a current price of $0.10 — trading 73.4% below its estimated fair value. The current EV-to-OCF is 201.15 and 2473.9% above the Medical Devices & Instruments industry median of 7.82. Biotricity's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Biotricity (BTCY), the current EV-to-OCF is 201.15 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotricity (BTCY) Overvalued in 2026?
Based on GuruFocus' analysis, Biotricity stock appears to be undervalued.
The current stock price of $0.10 is trading 73.4% below its estimated GF Value™ of $0.37.
GuruFocus considers Biotricity to be Possible Value Trap.
Key valuation signals for BTCY:
EV-to-OCF: 201.15
GF Value™: $0.37 vs. price of $0.10 (73.4% below fair value)
Industry Position: 2473.9% above the Medical Devices & Instruments median (#835 of 850)
No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
20GF Score
Get the complete analysis for BTCY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
